Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden

Journal of Epidemiology and Community Health

Volumn 50, Issue 2, 1996, Pages 190-195

  Lindholm, Lars ^a,c   Rosén, Måns ^b   Weinehall, Lars ^a   Asplund, Kjell ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b CENTRE FOR EPIDEMIOLOGY   (Sweden)

^c Department of Epidemiology and Public Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMMUNITY MEDICINE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVENTIVE MEDICINE; PROSPECTIVE STUDY; SWEDEN;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SWEDEN;

EID: 0029923388     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.50.2.190     Document Type: Article

References (46)

1. Brännström I, Rosén M, Wall S, Weinehall L. Local health planning and intervention - the case of a Swedish municipality. Scand J Prim Health Care 1988(Suppl 1):57-64.
2. Brännström I, Weinehall L, Persson L-Å, Wester P-O, Wall S. Changing social patterns of risk factors for cardiovascular disease in a Swedish community intervention programme. Int J Epidemiol 1993;22:1026-37.
3. Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol - time to change directions. Circulation 1992;86:1026-9.
4. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86: 1046-60.
5. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
6. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916-24.
7. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308: 373-9.
8. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304: 431-4.
9. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992; 305:15-19.
10. Kannel WB, Wolf PA, Garrison RJ. (eds). The Framingham study. An epidemiological investigation of cardiovascular disease. Bethesda: National Institutes of Health, 1987. NIH Publication No 87-2284.
11. Law MR, Wald NJ, Wu T, Hacksaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentrations and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308:363-6.
12. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall study. JAMA 1992;267:70-76.
13. Scandinavian Simvastin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastin survival study (4S). Lancet 1994;344:1383-9.
14. Keys A, Arvanis C, Blackburn H, et al. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA and London: Harvard University Press, 1980.
15. Statistics Sweden. Swedish socio-economic classification (SEI). Stockholm: Statistics Sweden, 1982. Reports on Statistical Co-ordination 1982:4.
16. Huhtasaari F, Asplund K, Wester P-O. Cardiovascular risk factors in the northern Sweden MONICA study. Acta Med Scand 1988;224:99-108.
17. Pindyck RS, Rubinfeld DL. Econometric models and economic forecasts. 3rd ed. Singapore: McGraw-Hill, 1991.
18. Freund RJ, Litell RC. SAS system for regression. Cary, NC: SAS Institute Inc, 1992.
19. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A. Myocardial infarction and coronary deaths in the World Health Organizations MONICA project. Circulation 1994;90:583-611.
20. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease: BMJ 1994;308: 362-72.
21. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765-74.
22. Lindholm L, Rosén M, Hellsten G. Are people willing to pay for a community-based preventive program. International Journal of Technology Assessment in Health Care 1994;10: 317-24.
23. Johannesson M, Hedbrant J, Jönsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Linkopïng: Linkopïng University, 1991. Centre for Medical Technology Assessment Report 3.
24. Levin L-Å, Jönsson B. Cost-effectiveness of thrombolysis: a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992;13:2-8.
25. Olsson G, Levin L-Å, Rehnqvist N. Economic consequences of postinfarction prophylaxis with β blockers: cost-effectiveness of metoprolol. BMJ 1987;294:339-42.
26. The Swedish Council on Technology Assessment in Health Care. Måttligt förhöjt blodtryck. Stockholm: Swedish Council on Technology Assessment in Health Care, 1994.
27. Report 121 (Summary available in English, "Moderately elevated blood pressure".)
28. Statistical yearbook of Sweden, 1992. Stockholm: Nordstedts Tryckeri AB, 1992.
29. Tengs TO, Adams M, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Boston: Center for Risk Analysis, Harvard School of Public Health, 1994.
30. Nissinen A, Tuomilehto J, Kottke TE, Puska P. Cost-effectiveness of the North-Karelia hypertension program 1972-1977. Med Care 1986;24:767-80.
31. Nissinen A, Tuomilehto J, Enlund H, Kottke TE. Costs and benefits of community programmes for the control of hypertension. Journal of Human Hypertension 1992;6: 473-9.
32. Kottke TE, Puska P, Feldman R, Salonen JT, Tuomilehto JA. A decline in earnings losses associated with a community based cardiovascular disease prevention project. Med Care 1982;20:663-75.
33. Altman DG, Flora JG, Fortman SP, Farquar JW. The cost-effectiveness of three smoking cessation programs. Am J Public Health 1987;77:162-65.
34. Nelson DJ, Lasater TM, Niknian M, Carleton RA. Cost effectiveness of different recruitment strategies for self-help smoking cessation programs. Health Education Research 1989;4:79-85.
35. Phillips CJ, Prowle MJ. Economics of a reduction in smoking: case study from Heartbeat Wales. J Epidemiology Community Health 1993;47:215-23.
36. Berwick DM, Cretin S, Keeler EB. Cholesterol, children and heart disease: an analysis of alternatives. New York/Oxford: Oxford University Press, 1980.
37. Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual interventions worth while? BMJ 1991;302:1119-22.
38. Kinosian B, Eisenberg JM. Cutting into cholesterol. JAMA 1988;259:2249-54.
39. Brännström I, Lindblad I-B. Mass communication and health promotion: The power of media in the public opinion. Health Communication 1994;6:21-36.
40. Perkins KA. Interactions among coronary heart disease risk factors. Annals of Behavioral Medicine 1989;11:3-11.
41. Kinlay S, O'Connel D, Evans D, Francis L. The validity of estimating heart disease reduction from a Framingham logistic equation. J Clin Epidemiol 1992;45:553-60.
42. Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: The concept, accuracy, and application. Am Heart J 1982;103:1031-39.
43. Leaverton PE, Sorlie PD, Kleinman JC, Dannenberg AL, Ingster-Moore I, Kannel WB, Cornoni-Huntley JC. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987;40:775-84.
44. Svärdsudd K, Tibblin G. Mortality and morbidity during 13-5 years' follow-up in relation to blood pressure. The study of men born in 1913. Acta Med Scand 1979;205: 483-92.
45. Sigurdsson JA, Bengtsson C, Lapidius L et al. Morbidity and mortality in relation to blood pressure and antihypertensive treatment. A 12-year follow-up study of a population sample of Swedish women. Acta Med Scand 1984;215:313-22.
46. Chambless LE, Dobson AJ, Patterson CC, Raines B. On the use of a logistic risk score in predicting risk of coronary heart disease. Stat Med 1990;9:385-96.